Global Antithrombotic Drugs Market
Global Antithrombotic Drugs Market

Antithrombotic Drugs Comprehensive Study by Type (Anti-Coagulants, Anti-Platelet Drugs, Thrombolytic Drugs), Application (Thromboembolic Disease Treatment, Prophylactic Treatment, Blood Clot Prevention, Hyperlipidemia Treatment), Administration (Oral Route, Parenteral Route) Players and Region - Global Market Outlook to 2024

Antithrombotic Drugs Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

May 2019 Edition 208 Pages 189 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study
Antithrombotic drugs are used to reduce the formation of blood clots. In the normal human body, blood flows smoothly through artery and veins. If clot or thrombus occurs in arteries or veins that result in blood blockage that may lead to heart attack and stroke. This disorders collectively are the most common cause of death and disability in the developed world. Hence the demand of antithrombotic drugs creates future opportunities in the pharmaceutical industry.

The market study is being classified by Type (Anti-Coagulants, Anti-Platelet Drugs and Thrombolytic Drugs), by Application (Thromboembolic Disease Treatment, Prophylactic Treatment, Blood Clot Prevention and Hyperlipidemia Treatment) and major geographies with country level break-up.

Sanofi (France), Abbott Laboratories (United States), Bayer AG (Germany), Boehringer Ingelheim GmbH (Germany), Eli Lilly and Company (United States), Johnson & Johnson Services Inc. (United States), Pfizer Inc. (United States), Alchemia (Australia), Amneal Pharms (United States) and GlaxoSmithKline Plc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Bristol Myers Squibb Company (United States), Genentech (United States), AstraZeneca Plc. (United States), Otsuka Pharmaceutical Co. Ltd (United States) and The Medicines Company (United States).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Antithrombotic Drugs market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Antithrombotic Drugs market by Type, Application and Region.

On the basis of geography, the market of Antithrombotic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Administration, the sub-segment i.e. Oral Route will boost the Antithrombotic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Cardiovascular Diseases, Blood-Related Diseases and Accidental Injuries
  • Increasing Aging Population

Market Trend
  • Increased Use of Anti-Thrombotic Drugs in Aged People

Restraints
  • Side Effects of the Drugs like Post-Operative Bleeding

Opportunities
  • Increasing Demand for Life Saving Drugs Due To Increasing Population

Challenges
  • Significant Drug Interactions


Market Leaders and their expansionary development strategies
On 03rd August 2018, Sanofi, a global biopharmaceutical company completes acquisition of Bioverativ Inc., American multinational biotechnology company.
On 25th September 2018, Health Canada approves Lovenox for the prevention of blood clot formation in the extra-corporeal circulation during hemodialysis in patients with end-stage kidney disease.


Key Target Audience
Hospitals, Specialty Clinics, Ambulatory Surgical Centers and General Pharmacies

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Anti-Coagulants
  • Anti-Platelet Drugs
  • Thrombolytic Drugs
By Application
  • Thromboembolic Disease Treatment
  • Prophylactic Treatment
  • Blood Clot Prevention
  • Hyperlipidemia Treatment
By Administration
  • Oral Route
  • Parenteral Route

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cardiovascular Diseases, Blood-Related Diseases and Accidental Injuries
      • 3.2.2. Increasing Aging Population
    • 3.3. Market Challenges
      • 3.3.1. Significant Drug Interactions
    • 3.4. Market Trends
      • 3.4.1. Increased Use of Anti-Thrombotic Drugs in Aged People
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antithrombotic Drugs, by Type, Application, Administration and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Antithrombotic Drugs (Value)
      • 5.2.1. Global Antithrombotic Drugs by: Type (Value)
        • 5.2.1.1. Anti-Coagulants
        • 5.2.1.2. Anti-Platelet Drugs
        • 5.2.1.3. Thrombolytic Drugs
      • 5.2.2. Global Antithrombotic Drugs by: Application (Value)
        • 5.2.2.1. Thromboembolic Disease Treatment
        • 5.2.2.2. Prophylactic Treatment
        • 5.2.2.3. Blood Clot Prevention
        • 5.2.2.4. Hyperlipidemia Treatment
      • 5.2.3. Global Antithrombotic Drugs by: Administration (Value)
        • 5.2.3.1. Oral Route
        • 5.2.3.2. Parenteral Route
      • 5.2.4. Global Antithrombotic Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Antithrombotic Drugs (Volume)
      • 5.3.1. Global Antithrombotic Drugs by: Type (Volume)
        • 5.3.1.1. Anti-Coagulants
        • 5.3.1.2. Anti-Platelet Drugs
        • 5.3.1.3. Thrombolytic Drugs
      • 5.3.2. Global Antithrombotic Drugs by: Application (Volume)
        • 5.3.2.1. Thromboembolic Disease Treatment
        • 5.3.2.2. Prophylactic Treatment
        • 5.3.2.3. Blood Clot Prevention
        • 5.3.2.4. Hyperlipidemia Treatment
      • 5.3.3. Global Antithrombotic Drugs by: Administration (Volume)
        • 5.3.3.1. Oral Route
        • 5.3.3.2. Parenteral Route
      • 5.3.4. Global Antithrombotic Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Antithrombotic Drugs (Price)
      • 5.4.1. Global Antithrombotic Drugs by: Type (Price)
  • 6. Antithrombotic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim GmbH (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson Services Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Alchemia (Australia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amneal Pharms (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline Plc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antithrombotic Drugs Sale, by Type, Application, Administration and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Antithrombotic Drugs (Value)
      • 7.2.1. Global Antithrombotic Drugs by: Type (Value)
        • 7.2.1.1. Anti-Coagulants
        • 7.2.1.2. Anti-Platelet Drugs
        • 7.2.1.3. Thrombolytic Drugs
      • 7.2.2. Global Antithrombotic Drugs by: Application (Value)
        • 7.2.2.1. Thromboembolic Disease Treatment
        • 7.2.2.2. Prophylactic Treatment
        • 7.2.2.3. Blood Clot Prevention
        • 7.2.2.4. Hyperlipidemia Treatment
      • 7.2.3. Global Antithrombotic Drugs by: Administration (Value)
        • 7.2.3.1. Oral Route
        • 7.2.3.2. Parenteral Route
      • 7.2.4. Global Antithrombotic Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Antithrombotic Drugs (Volume)
      • 7.3.1. Global Antithrombotic Drugs by: Type (Volume)
        • 7.3.1.1. Anti-Coagulants
        • 7.3.1.2. Anti-Platelet Drugs
        • 7.3.1.3. Thrombolytic Drugs
      • 7.3.2. Global Antithrombotic Drugs by: Application (Volume)
        • 7.3.2.1. Thromboembolic Disease Treatment
        • 7.3.2.2. Prophylactic Treatment
        • 7.3.2.3. Blood Clot Prevention
        • 7.3.2.4. Hyperlipidemia Treatment
      • 7.3.3. Global Antithrombotic Drugs by: Administration (Volume)
        • 7.3.3.1. Oral Route
        • 7.3.3.2. Parenteral Route
      • 7.3.4. Global Antithrombotic Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Antithrombotic Drugs (Price)
      • 7.4.1. Global Antithrombotic Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antithrombotic Drugs: by Type(USD Million)
  • Table 2. Antithrombotic Drugs Anti-Coagulants , by Region USD Million (2013-2018)
  • Table 3. Antithrombotic Drugs Anti-Platelet Drugs , by Region USD Million (2013-2018)
  • Table 4. Antithrombotic Drugs Thrombolytic Drugs , by Region USD Million (2013-2018)
  • Table 5. Antithrombotic Drugs: by Application(USD Million)
  • Table 6. Antithrombotic Drugs Thromboembolic Disease Treatment , by Region USD Million (2013-2018)
  • Table 7. Antithrombotic Drugs Prophylactic Treatment , by Region USD Million (2013-2018)
  • Table 8. Antithrombotic Drugs Blood Clot Prevention , by Region USD Million (2013-2018)
  • Table 9. Antithrombotic Drugs Hyperlipidemia Treatment , by Region USD Million (2013-2018)
  • Table 10. Antithrombotic Drugs: by Administration(USD Million)
  • Table 11. Antithrombotic Drugs Oral Route , by Region USD Million (2013-2018)
  • Table 12. Antithrombotic Drugs Parenteral Route , by Region USD Million (2013-2018)
  • Table 13. South America Antithrombotic Drugs, by Country USD Million (2013-2018)
  • Table 14. South America Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 15. South America Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 16. South America Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 17. Brazil Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 18. Brazil Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 19. Brazil Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 20. Argentina Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 21. Argentina Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 22. Argentina Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 23. Rest of South America Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 24. Rest of South America Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 25. Rest of South America Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 26. Asia Pacific Antithrombotic Drugs, by Country USD Million (2013-2018)
  • Table 27. Asia Pacific Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 28. Asia Pacific Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 29. Asia Pacific Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 30. China Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 31. China Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 32. China Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 33. Japan Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 34. Japan Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 35. Japan Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 36. India Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 37. India Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 38. India Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 39. South Korea Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 40. South Korea Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 41. South Korea Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 42. Taiwan Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 43. Taiwan Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 44. Taiwan Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 45. Australia Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 46. Australia Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 47. Australia Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 51. Europe Antithrombotic Drugs, by Country USD Million (2013-2018)
  • Table 52. Europe Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 53. Europe Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 54. Europe Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 55. Germany Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 56. Germany Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 57. Germany Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 58. France Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 59. France Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 60. France Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 61. Italy Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 62. Italy Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 63. Italy Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 64. United Kingdom Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 65. United Kingdom Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 66. United Kingdom Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 67. Netherlands Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 68. Netherlands Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 69. Netherlands Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 70. Rest of Europe Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 71. Rest of Europe Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 72. Rest of Europe Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 73. MEA Antithrombotic Drugs, by Country USD Million (2013-2018)
  • Table 74. MEA Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 75. MEA Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 76. MEA Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 77. Middle East Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 78. Middle East Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 79. Middle East Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 80. Africa Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 81. Africa Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 82. Africa Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 83. North America Antithrombotic Drugs, by Country USD Million (2013-2018)
  • Table 84. North America Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 85. North America Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 86. North America Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 87. United States Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 88. United States Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 89. United States Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 90. Canada Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 91. Canada Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 92. Canada Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 93. Mexico Antithrombotic Drugs, by Type USD Million (2013-2018)
  • Table 94. Mexico Antithrombotic Drugs, by Application USD Million (2013-2018)
  • Table 95. Mexico Antithrombotic Drugs, by Administration USD Million (2013-2018)
  • Table 96. Antithrombotic Drugs Sales: by Type(K Units)
  • Table 97. Antithrombotic Drugs Sales Anti-Coagulants , by Region K Units (2013-2018)
  • Table 98. Antithrombotic Drugs Sales Anti-Platelet Drugs , by Region K Units (2013-2018)
  • Table 99. Antithrombotic Drugs Sales Thrombolytic Drugs , by Region K Units (2013-2018)
  • Table 100. Antithrombotic Drugs Sales: by Application(K Units)
  • Table 101. Antithrombotic Drugs Sales Thromboembolic Disease Treatment , by Region K Units (2013-2018)
  • Table 102. Antithrombotic Drugs Sales Prophylactic Treatment , by Region K Units (2013-2018)
  • Table 103. Antithrombotic Drugs Sales Blood Clot Prevention , by Region K Units (2013-2018)
  • Table 104. Antithrombotic Drugs Sales Hyperlipidemia Treatment , by Region K Units (2013-2018)
  • Table 105. Antithrombotic Drugs Sales: by Administration(K Units)
  • Table 106. Antithrombotic Drugs Sales Oral Route , by Region K Units (2013-2018)
  • Table 107. Antithrombotic Drugs Sales Parenteral Route , by Region K Units (2013-2018)
  • Table 108. South America Antithrombotic Drugs Sales, by Country K Units (2013-2018)
  • Table 109. South America Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 110. South America Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 111. South America Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 112. Brazil Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 113. Brazil Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 114. Brazil Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 115. Argentina Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 116. Argentina Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 117. Argentina Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 118. Rest of South America Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 119. Rest of South America Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 120. Rest of South America Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 121. Asia Pacific Antithrombotic Drugs Sales, by Country K Units (2013-2018)
  • Table 122. Asia Pacific Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 123. Asia Pacific Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 124. Asia Pacific Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 125. China Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 126. China Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 127. China Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 128. Japan Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 129. Japan Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 130. Japan Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 131. India Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 132. India Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 133. India Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 134. South Korea Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 135. South Korea Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 136. South Korea Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 137. Taiwan Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 138. Taiwan Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 139. Taiwan Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 140. Australia Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 141. Australia Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 142. Australia Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 143. Rest of Asia-Pacific Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 144. Rest of Asia-Pacific Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 145. Rest of Asia-Pacific Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 146. Europe Antithrombotic Drugs Sales, by Country K Units (2013-2018)
  • Table 147. Europe Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 148. Europe Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 149. Europe Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 150. Germany Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 151. Germany Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 152. Germany Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 153. France Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 154. France Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 155. France Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 156. Italy Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 157. Italy Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 158. Italy Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 159. United Kingdom Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 160. United Kingdom Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 161. United Kingdom Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 162. Netherlands Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 163. Netherlands Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 164. Netherlands Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 165. Rest of Europe Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 166. Rest of Europe Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 167. Rest of Europe Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 168. MEA Antithrombotic Drugs Sales, by Country K Units (2013-2018)
  • Table 169. MEA Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 170. MEA Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 171. MEA Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 172. Middle East Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 173. Middle East Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 174. Middle East Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 175. Africa Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 176. Africa Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 177. Africa Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 178. North America Antithrombotic Drugs Sales, by Country K Units (2013-2018)
  • Table 179. North America Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 180. North America Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 181. North America Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 182. United States Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 183. United States Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 184. United States Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 185. Canada Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 186. Canada Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 187. Canada Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 188. Mexico Antithrombotic Drugs Sales, by Type K Units (2013-2018)
  • Table 189. Mexico Antithrombotic Drugs Sales, by Application K Units (2013-2018)
  • Table 190. Mexico Antithrombotic Drugs Sales, by Administration K Units (2013-2018)
  • Table 191. Antithrombotic Drugs: by Type(USD/Units)
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Antithrombotic Drugs: by Type(USD Million)
  • Table 203. Antithrombotic Drugs Anti-Coagulants , by Region USD Million (2019-2024)
  • Table 204. Antithrombotic Drugs Anti-Platelet Drugs , by Region USD Million (2019-2024)
  • Table 205. Antithrombotic Drugs Thrombolytic Drugs , by Region USD Million (2019-2024)
  • Table 206. Antithrombotic Drugs: by Application(USD Million)
  • Table 207. Antithrombotic Drugs Thromboembolic Disease Treatment , by Region USD Million (2019-2024)
  • Table 208. Antithrombotic Drugs Prophylactic Treatment , by Region USD Million (2019-2024)
  • Table 209. Antithrombotic Drugs Blood Clot Prevention , by Region USD Million (2019-2024)
  • Table 210. Antithrombotic Drugs Hyperlipidemia Treatment , by Region USD Million (2019-2024)
  • Table 211. Antithrombotic Drugs: by Administration(USD Million)
  • Table 212. Antithrombotic Drugs Oral Route , by Region USD Million (2019-2024)
  • Table 213. Antithrombotic Drugs Parenteral Route , by Region USD Million (2019-2024)
  • Table 214. South America Antithrombotic Drugs, by Country USD Million (2019-2024)
  • Table 215. South America Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 216. South America Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 217. South America Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 218. Brazil Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 219. Brazil Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 220. Brazil Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 221. Argentina Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 222. Argentina Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 223. Argentina Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 224. Rest of South America Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 225. Rest of South America Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 226. Rest of South America Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 227. Asia Pacific Antithrombotic Drugs, by Country USD Million (2019-2024)
  • Table 228. Asia Pacific Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 229. Asia Pacific Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 230. Asia Pacific Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 231. China Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 232. China Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 233. China Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 234. Japan Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 235. Japan Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 236. Japan Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 237. India Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 238. India Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 239. India Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 240. South Korea Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 241. South Korea Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 242. South Korea Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 243. Taiwan Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 244. Taiwan Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 245. Taiwan Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 246. Australia Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 247. Australia Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 248. Australia Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 249. Rest of Asia-Pacific Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 250. Rest of Asia-Pacific Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 251. Rest of Asia-Pacific Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 252. Europe Antithrombotic Drugs, by Country USD Million (2019-2024)
  • Table 253. Europe Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 254. Europe Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 255. Europe Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 256. Germany Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 257. Germany Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 258. Germany Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 259. France Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 260. France Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 261. France Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 262. Italy Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 263. Italy Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 264. Italy Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 265. United Kingdom Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 266. United Kingdom Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 267. United Kingdom Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 268. Netherlands Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 269. Netherlands Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 270. Netherlands Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 271. Rest of Europe Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 272. Rest of Europe Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 273. Rest of Europe Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 274. MEA Antithrombotic Drugs, by Country USD Million (2019-2024)
  • Table 275. MEA Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 276. MEA Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 277. MEA Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 278. Middle East Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 279. Middle East Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 280. Middle East Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 281. Africa Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 282. Africa Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 283. Africa Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 284. North America Antithrombotic Drugs, by Country USD Million (2019-2024)
  • Table 285. North America Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 286. North America Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 287. North America Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 288. United States Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 289. United States Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 290. United States Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 291. Canada Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 292. Canada Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 293. Canada Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 294. Mexico Antithrombotic Drugs, by Type USD Million (2019-2024)
  • Table 295. Mexico Antithrombotic Drugs, by Application USD Million (2019-2024)
  • Table 296. Mexico Antithrombotic Drugs, by Administration USD Million (2019-2024)
  • Table 297. Antithrombotic Drugs Sales: by Type(K Units)
  • Table 298. Antithrombotic Drugs Sales Anti-Coagulants , by Region K Units (2019-2024)
  • Table 299. Antithrombotic Drugs Sales Anti-Platelet Drugs , by Region K Units (2019-2024)
  • Table 300. Antithrombotic Drugs Sales Thrombolytic Drugs , by Region K Units (2019-2024)
  • Table 301. Antithrombotic Drugs Sales: by Application(K Units)
  • Table 302. Antithrombotic Drugs Sales Thromboembolic Disease Treatment , by Region K Units (2019-2024)
  • Table 303. Antithrombotic Drugs Sales Prophylactic Treatment , by Region K Units (2019-2024)
  • Table 304. Antithrombotic Drugs Sales Blood Clot Prevention , by Region K Units (2019-2024)
  • Table 305. Antithrombotic Drugs Sales Hyperlipidemia Treatment , by Region K Units (2019-2024)
  • Table 306. Antithrombotic Drugs Sales: by Administration(K Units)
  • Table 307. Antithrombotic Drugs Sales Oral Route , by Region K Units (2019-2024)
  • Table 308. Antithrombotic Drugs Sales Parenteral Route , by Region K Units (2019-2024)
  • Table 309. South America Antithrombotic Drugs Sales, by Country K Units (2019-2024)
  • Table 310. South America Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 311. South America Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 312. South America Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 313. Brazil Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 314. Brazil Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 315. Brazil Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 316. Argentina Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 317. Argentina Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 318. Argentina Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 319. Rest of South America Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 320. Rest of South America Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 321. Rest of South America Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 322. Asia Pacific Antithrombotic Drugs Sales, by Country K Units (2019-2024)
  • Table 323. Asia Pacific Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 324. Asia Pacific Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 325. Asia Pacific Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 326. China Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 327. China Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 328. China Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 329. Japan Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 330. Japan Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 331. Japan Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 332. India Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 333. India Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 334. India Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 335. South Korea Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 336. South Korea Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 337. South Korea Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 338. Taiwan Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 339. Taiwan Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 340. Taiwan Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 341. Australia Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 342. Australia Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 343. Australia Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 344. Rest of Asia-Pacific Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 345. Rest of Asia-Pacific Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 346. Rest of Asia-Pacific Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 347. Europe Antithrombotic Drugs Sales, by Country K Units (2019-2024)
  • Table 348. Europe Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 349. Europe Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 350. Europe Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 351. Germany Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 352. Germany Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 353. Germany Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 354. France Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 355. France Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 356. France Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 357. Italy Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 358. Italy Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 359. Italy Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 360. United Kingdom Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 361. United Kingdom Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 362. United Kingdom Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 363. Netherlands Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 364. Netherlands Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 365. Netherlands Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 366. Rest of Europe Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 367. Rest of Europe Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 368. Rest of Europe Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 369. MEA Antithrombotic Drugs Sales, by Country K Units (2019-2024)
  • Table 370. MEA Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 371. MEA Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 372. MEA Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 373. Middle East Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 374. Middle East Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 375. Middle East Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 376. Africa Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 377. Africa Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 378. Africa Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 379. North America Antithrombotic Drugs Sales, by Country K Units (2019-2024)
  • Table 380. North America Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 381. North America Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 382. North America Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 383. United States Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 384. United States Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 385. United States Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 386. Canada Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 387. Canada Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 388. Canada Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 389. Mexico Antithrombotic Drugs Sales, by Type K Units (2019-2024)
  • Table 390. Mexico Antithrombotic Drugs Sales, by Application K Units (2019-2024)
  • Table 391. Mexico Antithrombotic Drugs Sales, by Administration K Units (2019-2024)
  • Table 392. Antithrombotic Drugs: by Type(USD/Units)
  • Table 393. Research Programs/Design for This Report
  • Table 394. Key Data Information from Secondary Sources
  • Table 395. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antithrombotic Drugs: by Type USD Million (2013-2018)
  • Figure 5. Global Antithrombotic Drugs: by Application USD Million (2013-2018)
  • Figure 6. Global Antithrombotic Drugs: by Administration USD Million (2013-2018)
  • Figure 7. South America Antithrombotic Drugs Share (%), by Country
  • Figure 8. Asia Pacific Antithrombotic Drugs Share (%), by Country
  • Figure 9. Europe Antithrombotic Drugs Share (%), by Country
  • Figure 10. MEA Antithrombotic Drugs Share (%), by Country
  • Figure 11. North America Antithrombotic Drugs Share (%), by Country
  • Figure 12. Global Antithrombotic Drugs: by Type K Units (2013-2018)
  • Figure 13. Global Antithrombotic Drugs: by Application K Units (2013-2018)
  • Figure 14. Global Antithrombotic Drugs: by Administration K Units (2013-2018)
  • Figure 15. South America Antithrombotic Drugs Share (%), by Country
  • Figure 16. Asia Pacific Antithrombotic Drugs Share (%), by Country
  • Figure 17. Europe Antithrombotic Drugs Share (%), by Country
  • Figure 18. MEA Antithrombotic Drugs Share (%), by Country
  • Figure 19. North America Antithrombotic Drugs Share (%), by Country
  • Figure 20. Global Antithrombotic Drugs: by Type USD/Units (2013-2018)
  • Figure 21. Global Antithrombotic Drugs share by Players 2018 (%)
  • Figure 22. Global Antithrombotic Drugs share by Players (Top 3) 2018(%)
  • Figure 23. Global Antithrombotic Drugs share by Players (Top 5) 2018(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi (France) Revenue: by Geography 2018
  • Figure 27. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 28. Abbott Laboratories (United States) Revenue: by Geography 2018
  • Figure 29. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 31. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2018
  • Figure 33. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 35. Johnson & Johnson Services Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson Services Inc. (United States) Revenue: by Geography 2018
  • Figure 37. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 39. Alchemia (Australia) Revenue, Net Income and Gross profit
  • Figure 40. Alchemia (Australia) Revenue: by Geography 2018
  • Figure 41. Amneal Pharms (United States) Revenue, Net Income and Gross profit
  • Figure 42. Amneal Pharms (United States) Revenue: by Geography 2018
  • Figure 43. GlaxoSmithKline Plc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. GlaxoSmithKline Plc. (United States) Revenue: by Geography 2018
  • Figure 45. Global Antithrombotic Drugs: by Type USD Million (2019-2024)
  • Figure 46. Global Antithrombotic Drugs: by Application USD Million (2019-2024)
  • Figure 47. Global Antithrombotic Drugs: by Administration USD Million (2019-2024)
  • Figure 48. South America Antithrombotic Drugs Share (%), by Country
  • Figure 49. Asia Pacific Antithrombotic Drugs Share (%), by Country
  • Figure 50. Europe Antithrombotic Drugs Share (%), by Country
  • Figure 51. MEA Antithrombotic Drugs Share (%), by Country
  • Figure 52. North America Antithrombotic Drugs Share (%), by Country
  • Figure 53. Global Antithrombotic Drugs: by Type K Units (2019-2024)
  • Figure 54. Global Antithrombotic Drugs: by Application K Units (2019-2024)
  • Figure 55. Global Antithrombotic Drugs: by Administration K Units (2019-2024)
  • Figure 56. South America Antithrombotic Drugs Share (%), by Country
  • Figure 57. Asia Pacific Antithrombotic Drugs Share (%), by Country
  • Figure 58. Europe Antithrombotic Drugs Share (%), by Country
  • Figure 59. MEA Antithrombotic Drugs Share (%), by Country
  • Figure 60. North America Antithrombotic Drugs Share (%), by Country
  • Figure 61. Global Antithrombotic Drugs: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Sanofi (France)
  • Abbott Laboratories (United States)
  • Bayer AG (Germany)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly and Company (United States)
  • Johnson & Johnson Services Inc. (United States)
  • Pfizer Inc. (United States)
  • Alchemia (Australia)
  • Amneal Pharms (United States)
  • GlaxoSmithKline Plc. (United States)
Additional players considered in the study are as follows:
Bristol Myers Squibb Company (United States) , Genentech (United States) , AstraZeneca Plc. (United States) , Otsuka Pharmaceutical Co. Ltd (United States) , The Medicines Company (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation